Global fibrinolytic capacity is decreased in girls with premature adrenarche: A new pathological finding?

Journal of Pediatric Endocrinology and Metabolism

Volumn 18, Issue 12, 2005, Pages 1373-1381

  Andiran, Nesibe ^a   Yordam, Nurşen ^a   Kirazli, Şerafettin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Fasting glucose; Global fibrinolytic capacity; Insulin ratio; Polycystic ovary syndrome; Premature adrenarche; Sex hormone binding globulin

Indexed keywords

CHOLESTEROL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADRENARCHE; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE AGE; BREAST DEVELOPMENT; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOLYSIS; GLOBAL FIBRINOLYTIC CAPACITY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PRECOCIOUS PUBERTY; PROVOCATION TEST; RISK ASSESSMENT; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

EID: 30944447655     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2005.18.12.1373     Document Type: Article

References (33)

1. Rosenfield RL. Normal and almost normal precocious variations in pubertal development: premature pubarche and premature telarche revisited. Horm Res 1994; 41 (Suppl 2): 7-13.
2. Ibanez L, Potau N, Carroscosa A. Androgens in adrenarche and pubarche. In: Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women. Philadelphia, PA: Lippincott-Raven, 1997; 73-84.
3. Ibanez L, Potau N, Zampolli M, Rique S, Saenger P, Canascosa A. Hyperinsulinemia and decreased insulin-like-growth factor binding protein-1 are common features in prepubertal and postpubertal girls with a history of premature pubarche. J Clin Endocrinol Metab 1997; 82: 2283-2288.
4. Ibanez L, Potau N, Zampolli M, Prat N, Virdis R, Vicens-Calvet E, Canascosa A. Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1996; 81: 1237-1243.
5. Ibanez L, Potau N, Chacon P, Pascual C, Canascosa A. Hyperinsulinemia, dyslipidemia and cardiovascular risk in girls with a history of premature pubarche. Diabetologia 1998; 41: 1057-1063.
6. Ibanez L, Potau N, Virdis R, Zampolli M, Terzi C, Gussinye M, Canascosa A, Vicens-Calvet E. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76: 1599-1603.
7. Ibanez L, Potau N, de Zegher F. Anovulation after precocious pubarche: early markers and time course in adolescence. J Clin Endocrinol Metab 1999; 84: 2691-2695.
8. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche. Ontogeny of the low-birthweight effect. Clin Endocrinol 2001; 55: 667-672.
9. Ibanez L, Potau N, Albisu M. Post-pubertal assessment in girls with premature pubarche: clinical, biochemical, and echographic findings. Horm Res 1990; 33 (Suppl 3): 37 (Abst).
10. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-780.
11. Guzick DS, Talbott EO, Sutton-Tyrell K, Herzog HC, Kuller LH, Walfson SK Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 1996; 174: 1224-1229; discussion 1229-1232.
12. Talbott E, Guzick D, Sutton-Tyrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20: 2414-2421.
13. Cibula D, Cifkova R, Fanta M, Polende R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000; 15: 785-789.
14. Amiral J. The global fibrinolytic capacity. Fibrinolysis 1996; 10: 95-99.
15. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002; 87: 3871-3875.
16. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Merriman GR, eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell, 1992; 377-384.
17. Ibanez L, Potau N, Zampolli M. Functional adrenal hyperandrogesism is a common feature in postpubertal girls with a history of premature pubarche: relationship to hyperinsulinemia and ovarian androgen excess. Horm Res 1997; (Suppl 2): 110 (Abst).
18. Rosenfield RL. Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steridogenesis and that hyperinsulinemia may be involved [Editorial]. J Clin Endocrinol Metab 1996; 81: 878-880.
19. Ibanez L, Potau N, Zampolli M, Prat N, Virdis R, Vicens-Calvet E, Canascosa A. Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1996; 81: 1237-1243.
20. Khan R. Consensus Development Conference on Insulin Resistance November 5-6, 1997. Diabetes Care 1998; 21: 310-313.
21. Silfen ME, Manibo AM, McMahon DJ, Levine LS, Murphy AR, Oberfield SE. Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ratio may be a simple and useful measure. J Clin Endocrinol Metab 2001; 86: 2863-2868.
22. Vuguin P, Saenger P, Dimartino-Nardi J. Fasting glucose insulin ratio: a useful measure of insulin resistance in girls with premature adrenarche. J Clin Endocrinol Metab 2001; 86: 4618-4621.
23. Oppenheimer E, Linder B, Di Martino-Nardi J. Decreased insulin sensitivity in prepubertal girls with premature pubarche and acanthosis nigricans. J Clin Endocrinol Metab 1995; 80: 614-618.
24. Nestler JE, Strauss JF III. Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am 1991; 20: 807-823.
25. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-89.
26. Birkeland KI, Hanssen KF, Torjesen PA, Vaaler S. Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes (NIDDM). J Clin Endocrinol Metab 1993; 76: 275-278.
27. Preziosi P, Barrett-Connor E, Papoz L, Roger M, Saint-Paul M, Nahoul K, Simon D. Interrelation between plasma sex hormone-binding globulin and plasma insulin in healthy adult women: the Telecom Study. J Clin Endocrinol Metab 1993; 76: 283-287.
28. Nestler JE. Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? [Editorial). J Clin Endocrinol Metab 1993; 76: 273-274.
29. Ibanez L, Aulesa C, Poatu N, Ong K, Dunger DB, de Zegher F. Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome? Pediatr Res 2002; 51: 244-248.
30. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996; 45: 623-629.
31. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 236-241.
32. Dahlgren E, Janson PO, Johanson S, Lapidus L, Lindstedt G, Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994; 61: 455-460.
33. Atiomo WU, Fox R, Condon JE, Shaw S, Friend J, Prentice AG, Wilkin TJ. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2000; 52: 487-492.